Align Tech에 대한 매도 수량은 투자자에게 Align Tech의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Align Tech (NASDAQ:ALGN) 주식, 공매도 수량 보고

Align Tech

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Politics

Trading Ideas

ALGN

NVDA

PYPL

VRTX

WYNN

전 대통령 도널드 트럼프는 이전에 백악관에서 4년 동안 재직한 경험이 있기 때문에, 그가 2024년 대선에서 승리하여 두 번째 임기를 수행할 경우 어떤 주식과 섹터가 혜택을 볼 수 있을지 투자자들이 파악하는 데 도움이 될 수 있다.

트럼프 대통령 시기인 2017년 S&amp;P 500에서 가장 우수한 성과를 거둔 10개 주식: 역사가 반복될까?

News

Movers

BEKE

FSLR

FUTU

NTES

TSLA

미국에 상장된 중국 기업들의 주가는 약세로 인해 지난주 상승폭을 잃었다. 중국은 투자자들의 경기 부양 기대에 미치지 못해 2주 연속 상승세를 보인 후 하락세를 보인 것으로 알려졌다.

리 오토, 테슬라 및 니오는 지난주 최악의 성과를 보인 11개 대형주 중 일부 (10월 7일 - 10월 11일)

Earnings

Guidance

Health Care

After-Hours Center

치과 교정에 사용되는 3D 디지털 스캐너와 인비절라인(Invisalign) 투명 교정 장치를 생산하는 미국 제조업체 얼라인 테크놀로지(NASDAQ:ALGN)의 주가는 회사가 2분기 재무 결과를 보고하고 약한 가이던스를 발표한 후 수요일 시간외 세션에서 하락했다.

얼라인 테크놀로지는 약한 2분기 매출 실적과 3분기 가이던스 발표 후 주가 하락

Align Technology Inc

B of A Securities analyst Michael Ryskin maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Underperform and raises the price target from $200 to $206.

Price Target

Analyst Ratings

B of A Securities Maintains Underperform on Align Tech, Raises Price Target to $206

On Wednesday,&nbsp;Patient Square Capital, a healthcare investment firm, agreed to acquire&nbsp;Patterson Companies, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>), a dental and animal health product distributor, for&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42433177/patterson-companies-announces-definitive-agreement-to-be-acquired-by-patient-square-capital-for-31" rel="noreferrer noopener">approximately $4.1 billion</a>.
During its second-quarter earnings release, the company announced it is exploring strategic options, including a sale or merger,&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42342667/dental-supplies-patterson-companies-evaluates-strategic-alternatives-after-mixed-q2-earnings-amid-challenging-end-market-environment" rel="noreferrer noopener">to boost shareholder value</a>.
William Blair notes that based on Patient Square Capital&#8217;s portfolio, which doesn&#8217;t include dental or animal health companies, regulatory hurdles for this deal are unlikely.
Additionally, the analyst&#8217;s dental valuation analysis suggests the offer for Patterson is strong, making it unlikely that higher bids will emerge during the 40-day window for competing offers.
The valuation analysis includes Align Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), Dentsply Sirona Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), Henry Schein Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>), Envista Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) and Europe-listed Straumann Holding.
William Blair writes that most dental companies they cover are trading at or near their lowest valuations in 15 years, as investor interest has declined due to ongoing macroeconomic challenges.
Most recently,&nbsp;Dentsply Sirona revised its 2024 outlook due to market pressures impacting U.S. equipment, legislative changes affecting the direct-to-consumer aligner business model, and the voluntary&nbsp;suspension of sales, marketing, and shipments of Byte Aligners <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814727/dentsply-sirona-stock-sinks-on-dismal-2024-guidance-blames-macroeconomic-competitiv" rel="noreferrer noopener">and Impression Kits</a>.
Henry Schein&#8217;s third-quarter global dental segment sales were $1.9 billion, down 1.6%, and medical segment sales increased by 2.9% (down 4.8% internally) <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752173/henry-schein-q3-earnings-sees-recovery-from-cyber-incident-says-dental-equipment-business-shows-sta" rel="noreferrer noopener">to $1.1 billion</a>.
While it&#8217;s still early to gauge investor reactions, the analyst is considering whether Patterson&#8217;s acquisition might stabilize valuations and boost demand in the dental sector.
The analyst writes the move could support valuations and signal a potential recovery in the market, making many dental stocks appealing from a risk/reward perspective.
Among these, William Blair sees Align as having the greatest potential for stock growth, driven by improving market conditions and gains in both earnings and valuation.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42465586/gevo-and-lg-chem-push-ahead-on-eto-commercialization-for-sustainable-aviation-and-bio-propylene-markets" target="_blank" rel="noreferrer noopener">Gevo And LG Chem Double Down On Ethanol-To-Olefins Tech: Details</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Large Cap

General

HSIC

NVST

PDCO

XRAY

What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players?

<ul>
<li>Invisalign&#xAE; Palatal Expanders offer doctors a removeable, safe, and clinically effective alternative to traditional palatal expanders.</li>
<li>With Invisalign First&#x2122; aligners and Invisalign&#xAE; Palatal Expanders, Align Technology now provides doctors with a full early intervention treatment solution, including both skeletal (orthopedic) and dental (orthodontic) arch expansion.</li>
<li>The Invisalign Palatal Expander System has also completed registration with the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA).</li>
<li>Both approvals are for broad patient applicability, including growing children, teens, and adults (with surgery or other techniques).</li>
</ul>
Align Technology, Inc. ("Align") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) a leading global medical device company that designs, manufactures, and sells the Invisalign&#xAE; System of clear aligners, iTero&#x2122; intraoral scanners, and exocad&#x2122; CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has received CE Mark in Europe under the Medical Device Regulation (MDR 2017/745) for Align's Invisalign&#xAE; Palatal Expander System. The Invisalign Palatal Expander System has also completed registration with MHRA for the United Kingdom and overseas territories.
Both approvals are for broad patient applicability, including growing children, teens, and adults (with surgery or other techniques).
These approvals mark a significant milestone in Align's efforts to enhance clinical outcomes and efficiency in orthodontics.
The Invisalign Palatal Expander System is a modern and innovative direct 3D printed device based on proprietary and patented technology. Invisalign Palatal Expanders are intended for use in rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed, or permanent dentition during treatment of patients.

Global

Align Technology Has Received CE Mark In Europe For The Invisalign Palatal Expander System

Needham analyst David Saxon reiterates Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Align Tech

Former President Donald Trump previously spent four years in the White House, which could help investors know which stocks and sectors could benefit under a second term if he wins the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
Here's a look back at the top performing stocks in 2017, Trump's first year in the White House.
Top Performing 2017 Stocks: The stock markets saw impressive gains in 2017, which were among the best ever for a president's <a href="https://www.benzinga.com/markets/futures/18/01/11066769/the-stock-markets-rally-under-trump-among-the-best-ever-heres-how-his">first year in the White House.</a>
The S&amp;P 500, which is tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), gained 21.7% in 2017, an impressive gain to the +12.0% increase in 2016, as presidential election years have historically produced outperformance to other years.
With the potential for Trump to be re-elected in 2024, here's a look back at the top 10 performing stocks in the S&amp;P 500 from 2017, as reported previously by <a href="https://www.marketwatch.com/story/biggest-sp-500-winners-and-losers-of-2017-tech-health-care-and-home-builders-lead-2017-12-29">Marketwatch</a>.
<ol>
<li>NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>): +132%, utilities</li>
<li>Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>): +131%, health care</li>
<li>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>): +103%, health care</li>
<li>Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>): +95%, consumer discretionary</li>
<li>Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): +89%, industrials</li>
<li>Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>): +88%, technology</li>
<li>D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>): +87%, consumer discretionary, homebuilders</li>
<li>PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): +87%, technology</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): +81%, technology</li>
<li>Pulte Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>): 81%, consumer discretionary, homebuilders</li>
</ol>
The top 10 stocks in 2017 likely saw gains related to reasons that didn't have to do with Trump being president, but there are also some common themes and some potential connections to the former president.
The results show that health care, consumer discretionary and technology stocks were among the top-performing sectors.
Of particular note is Micron and Nvidia, both ranking in the top 10, a potential positive for the semiconductor sector under a Trump presidency.
Another key trend could be two homebuilders ranking among the top 10 best-performing stocks in 2017. Homebuilders have been a popular sector to watch under a possible Kamala Harris win with the current vice president and Trump running on a platform of <a href="https://www.benzinga.com/general/politics/24/08/40424431/harris-warns-trump-tax-plan-will-devastate-americans-vows-to-go-after-bad-actors-behind-food-pri">building more homes</a> for the middle class.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent102824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: While past results don't guarantee future results, sometimes market trends can show patterns and signs of what to come.
Based on the top-performing stocks in 2017, investors may want to prepare for some <a href="https://www.benzinga.com/markets/equities/24/10/41213583/what-a-trump-win-could-mean-for-financial-energy-stocks-lessons-from-2016">exposure to health care</a>, utilities, semiconductors and homebuilders if Trump wins the 2024 election.
With less than two weeks until the 2024 election, investors are likely positioning their portfolios based on a Trump or Harris win in some regards. With a close election predicted, investors may want to look to sectors that could benefit under either candidate.
Freedom Capital Markets Chief Global Strategist Jay Woods previously shared some <a href="https://www.benzinga.com/etfs/sector-etfs/24/08/40515453/exclusive-trump-or-harris-12-stocks-2-etfs-could-win-no-matter-whos-president-says-market-strate">sectors and stocks to watch</a> with Benzinga that could benefit regardless of whether Trump or Harris wins the 2024 election.
Woods named defense stocks and cybersecurity stocks as two of the top sectors to watch ahead of the 2024 election.
"I think you've got to watch this sector closely," Woods said of the defense sector.
Woods said defense stocks could continue to benefit from geopolitical concerns and a lot of bad things happening in the world.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/10/41534317/if-trump-wins-2024-election-in-landslide-bettors-could-make-5x-20x-their-bets-at-uk-sports">If Trump Wins 2024 Election In Landslide, Bettors Could Make 5X, 20X Their Bets At UK Sportsbook</a></li>
</ul>
Photo: Shutterstock

These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?

Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) shares are trading higher by 3% to $223.00 Friday morning after the company announced plans to repurchase $275 million of its common stock as part of a $1 billion stock repurchase program <a href="https://www.benzinga.com/pressreleases/24/10/b41543440/align-technology-announces-275-million-open-market-repurchase">approved in January 2023</a>.
What Else: CFO John Morici highlighted that this buyback reflects confidence in the company&#8217;s financial strength and growth potential within the orthodontic industry. 
The repurchase will occur through open market transactions under a Rule 10b5-1 trading plan, concluding by January 2025, and will be funded from Align's cash reserves. As of September 30, Align reported 74.8 million shares outstanding and over $1 billion in cash.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41536518/bitcoin-gains-ethereum-dogecoin-muted-amid-tesla-powered-stocks-rally-analyst-highlights-m">Bitcoin Gains, Ethereum, Dogecoin Muted Amid Tesla-Powered Stocks Rally</a>
Why This Matters: A stock repurchase often leads to a rise in the stock price because it reduces the number of shares outstanding, effectively increasing the value of each remaining share. 
This buyback signals that Align Technology's management is confident in the company&#8217;s financial health and growth prospects, making the stock more attractive to investors. 
Additionally, by using cash reserves to buy back shares, Align demonstrates strong cash flow, which can reinforce investor confidence. These factors together often drive up demand for the stock.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41536387/cathie-woods-ark-sells-22m-worth-of-tesla-shares-following-blockbuster-q3-rally">Cathie Wood&#8217;s Ark Sells $22M Worth Of Tesla Shares Following Blockbuster Q3 Rally</a>
<h2 class="wp-block-heading">Is ALGN A Good Stock To Buy?</h2>
An investor or trader's decision to buy or sell a stock is unique to their time horizon and risk tolerance. Many typical investors evaluate earnings growth and valuation on a particular stock before making a decision. 
For example, for Align Tech, you'll notice that earnings in its last quarter grew 1.73% <a href="https://www.benzinga.com/quote/ALGN/earnings">source</a>. As an investor, you'll want to decide whether that's better or worse than what you'd like to see among stocks in your portfolio. 
There are many different valuation metrics that may help you make a decision. Find more on <a href="https://www.benzinga.com/quote/ALGN">Align Tech's quote page</a>, or if you'd like a deeper dive in an advanced program, try <a href="https://pro.benzinga.com">Benzinga PRO</a> for free.
ALGN has a 52-week high of $335.40 and a 52-week low of $176.34.

Why Align Technology (ALGN) Stock Is Trading Higher

WIIM

Align Technology shares are trading higher after the company announced it plans to purchase $275 million worth of stock in the open market as part of its $1 billion repurchase program.

Align Technology, Inc. ("Align") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), a leading global medical device company that designs, manufactures, and sells the Invisalign&#xAE; System of clear aligners, iTero&#x2122; intraoral scanners, and exocad&#x2122; CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $275 million of Align's common stock through open market repurchases under Align's $1.0 billion stock repurchase program that was approved by Align's Board of Directors in January 2023.

Buybacks

Align Technology Plans $275M Open Market Repurchase Under Align's $1B Stock Repurchase Program

Morgan Stanley analyst Erin Wright maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and lowers the price target from $310 to $280.

Morgan Stanley Maintains Overweight on Align Tech, Lowers Price Target to $280

Stifel analyst Jonathan Block maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Buy and lowers the price target from $285 to $275.

Stifel Maintains Buy on Align Tech, Lowers Price Target to $275

Evercore ISI Group analyst Elizabeth Anderson maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Outperform and lowers the price target from $270 to $250.

Evercore ISI Group Maintains Outperform on Align Tech, Lowers Price Target to $250

Align Technology shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Whales with a lot of money to spend have taken a noticeably bullish stance on Align Tech.
Looking at options history for Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $249,770 and 4, calls, for a total amount of $284,927.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $125.0 and $212.5 for Align Tech, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Align Tech's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Align Tech's significant trades, within a strike price range of $125.0 to $212.5, over the past month.
<h3>Align Tech Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729781127_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$124.9</td>
<td>$122.5</td>
<td>$122.5</td>
<td>$125.00</td>
<td>$183.7K</td>
<td style="text-align: right;">15</td>
<td>15</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.2</td>
<td>$1.6</td>
<td>$2.0</td>
<td>$170.00</td>
<td>$120.0K</td>
<td style="text-align: right;">171</td>
<td>1.2K</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.7</td>
<td>$2.15</td>
<td>$2.3</td>
<td>$170.00</td>
<td>$45.7K</td>
<td style="text-align: right;">171</td>
<td>201</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$2.4</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$212.50</td>
<td>$42.0K</td>
<td style="text-align: right;">6</td>
<td>201</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.5</td>
<td>$0.95</td>
<td>$2.1</td>
<td>$170.00</td>
<td>$42.0K</td>
<td style="text-align: right;">171</td>
<td>600</td>
</tr>
</tbody>
</table>

<h3>About Align Tech</h3>
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Having examined the options trading patterns of Align Tech, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Align Tech</h3>
<ul>
<li>With a volume of 793,567, the price of ALGN is up 5.94% at $220.0. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 97 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Align Tech with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Unpacking the Latest Options Trading Trends in Align Tech

Piper Sandler analyst Jason Bednar maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and lowers the price target from $285 to $275.

Piper Sandler Maintains Overweight on Align Tech, Lowers Price Target to $275

Baird analyst Jeff Johnson maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Outperform and lowers the price target from $325 to $276.

Baird Maintains Outperform on Align Tech, Lowers Price Target to $276

Align Technology shares are trading lower after the company reported mixed Q3 financial results.

<ul>
<li>For&nbsp;Q4&#39;24, it expects Clear Aligner volume and ASP to be slightly up sequentially</li>
<li>Expects&nbsp;Q4&#39;24 GAAP operating margin to be slightly lower than&nbsp;14.0%&nbsp;primarily due to restructuring charges related to severance as it adjusts headcount for the existing business environment.&nbsp;</li>
<li>It anticipates Q4&#39;24 non-GAAP operating margin to be slightly up sequentially</li>
</ul>

Align Technology Expects Q4 Worldwide Revenues Of $995M - $1.015B

Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) reported quarterly earnings of $2.35 per share which beat the analyst consensus estimate of $2.31 by 1.73 percent. This is a 9.81 percent increase over earnings of $2.14 per share from the same period last year. The company reported quarterly sales of $977.87 million which missed the analyst consensus estimate of $987.34 million by 0.96 percent. This is a 1.84 percent increase over sales of $960.21 million the same period last year.

Earnings Beats

Earnings Misses

Align Tech Q3 2024 Adj EPS $2.35 Beats $2.31 Estimate, Sales $977.87M Miss $987.34M Estimate

Piper Sandler analyst Jason Bednar maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and lowers the price target from $315 to $285.

Piper Sandler Maintains Overweight on Align Tech, Lowers Price Target to $285

Align Technology (ALGN) announced that it has received CE Mark in Europe under the Medical Device Regulation for Align's Invisalign Palatal Expande...

Align receives CE Mark in Europe for Invisalign Palatal Expander System

In a report released today, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Align Tech (ALGN – Research Report), with a price target...

Stifel Nicolaus Sticks to Its Buy Rating for Align Tech (ALGN)

Align Technology Inc.'s third-quarter results did not show much progress towards regaining its old growth momentum, but some small signs of improvement were enough to give shares a recent boost.

Align Technology: Working To Regain Momentum While Cutting Costs

Mizuho initiated coverage of Align Technology (ALGN) with an Outperform rating and $295 price target Nearly every subsegment of the global dental/o...

Align Technology initiated with an Outperform at Mizuho

LRT Capital Management November 2024 Investor Update

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

GE Vernova initiated, Merck upgraded: Wall Street's top analyst calls

Steven Valiquette, an analyst from Mizuho Securities, has initiated a new Buy rating on Align Tech (ALGN). Steven Valiquette has given his Buy rati...

Strategic Buy Recommendation for Align Technology Amidst Market Recovery and Growth Potential

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revance Therapeutics (RVNC – Research Report), Syn...

Analysts Conflicted on These Healthcare Names: Revance Therapeutics (RVNC), Syndax Pharmaceuticals (SNDX) and Align Tech (ALGN)

BNY Mellon Small/Mid Cap Growth Fund Q3 2024 Commentary

BofA raised the firm's price target on Align Technology (ALGN) to $206 from $200 and keeps an Underperform rating on the shares. The Life Sciences ...

Align Technology price target raised to $206 from $200 at BofA

ALEC

APOS

AXON

AZPN

BKAG

BKCI

BKEM

BKGI

BKHY

BKIE

BKLC

BKMC

BKSE

BKUI

CASY

CELH

CFLT

CGNX

CIGI

COHR

CSGP

DINO

DOCS

DXCM

ENSG

EXPO

FRPT

GDRX

HUBS

INSP

KVYO

LFMD

MKTX

PLNT

PSTG

RGEN

RVNC

SNDX

SOLV

SRPT

TALK

TNET

TRMB

VEEV

Press Releases

Align Technology to Announce Third Quarter 2024 Results on October 23, 2024

Align Technology Introduces Invisalign Smile Architect™ With Multiple Treatment Plans, Further Enabling Ortho Restorative Digital Dentistry Treatment Options

Align Technology Announces iTero™ Intraoral Scanner Product Innovations That Enhance Digital Dentistry Workflows and Integrated Treatment Options in Oral Health, Restorative, and Ortho Treatment in General Dentistry Practices

ALIGN TECHNOLOGY ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS

Frank Quinn to Rejoin Align Technology as Executive Vice President and Managing Director of the Americas Region

Align Technology Announces $275 Million Open Market Repurchase

Align Technology to Speak at Upcoming Financial Conferences

Align Technology Opens 2025 Annual Research Program to Advance Orthodontic and Dental Patient Care

Align Technology Hosts the 2024 Invisalign™ Ortho Summit, Its Premier Education Event to Enhance Digital Practice Transformation and Treatment Experiences for Patients, Teams, and Practices

Align Technology Has Received CE Mark in Europe for the Invisalign® Palatal Expander System to Address Skeletal and Dental Expansion in Growing Patients, Including Teenage Patients

Comments

Align Tech

매도 수량

Align Tech (NASDAQ:ALGN) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌